Maryland State Retirement & Pension System Reduces Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Maryland State Retirement & Pension System decreased its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 16,608 shares of the company’s stock after selling 127 shares during the period. Maryland State Retirement & Pension System’s holdings in Prestige Consumer Healthcare were worth $1,297,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Prestige Consumer Healthcare by 3.2% in the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after purchasing an additional 8,533 shares during the period. Geode Capital Management LLC raised its stake in Prestige Consumer Healthcare by 4.0% in the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after buying an additional 50,961 shares in the last quarter. Avior Wealth Management LLC raised its stake in Prestige Consumer Healthcare by 1,570.7% in the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock worth $668,000 after buying an additional 8,042 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Prestige Consumer Healthcare by 5.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock worth $49,667,000 after buying an additional 33,844 shares in the last quarter. Finally, Barclays PLC raised its stake in Prestige Consumer Healthcare by 346.3% in the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after buying an additional 71,730 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Insider Activity

In other news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $84.12 on Friday. The firm has a market capitalization of $4.17 billion, a PE ratio of 19.70, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $90.04. The company’s fifty day moving average price is $82.46 and its 200-day moving average price is $78.62.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on PBH shares. Royal Bank of Canada boosted their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a research note on Friday. Oppenheimer boosted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. DA Davidson upped their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Finally, Canaccord Genuity Group upped their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and an average target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.